US › Healthcare

Vyome Holdings, Inc. (HIND)

US · Healthcare · Biotechnology

$1.96+0.51%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$26,955

Revenue YoY

-97.8%

Net profit

$-685,556

EPS

$-0.10

EPS estimate

$-0.19

Net margin

-2,543.3%

EPS came in at -0.10 against a street estimate of -0.19 — a beat of 47.4%.

Key statistics

Market cap

$14.1M

Forward P/E

0.0

P/B

2.39

Book value

$0.86

EPS (TTM)

$-1.57

52-week high

$6.63

52-week low

$1.75

50-day MA

$2.17

200-day MA

$2.62

Analyst view

with an average price target of $8.83.

Shareholding

Insiders

52.88%

Institutions

2.18%

Largest institutional holders

Fund	Stake
Citadel Advisors Llc	0.37%
Geode Capital Management, LLC	0.37%
UBS Group AG	0.32%
The Colony Group LLC	0.21%
Vanguard Fiduciary Trust Co	0.17%
Vanguard Capital Management, LLC	0.13%
Royal Bank of Canada	0.08%
Tower Research Capital LLC	0.02%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vyome Holdings, Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.